Literature DB >> 11333047

Atrial arrhythmia suppression by atrial overdrive pacing: pacemaker Holter assessment.

K J Ward1, J E Willett, C Bucknall, J S Gill, K Kamalvand.   

Abstract

The purpose of this study was to assess the efficacy of overdrive, single-site right atrial appendage pacing to reduce the burden of atrial fibrillation (AF) when compared with a standard lower rate limit of 60 bpm. This was verified by using the pacemaker's Holter. Eighteen subjects with a pre-implant history of paroxysmal AF and implanted DDDR mode-switching pacemakers were recruited. The pacemaker lower rate limit was programmed in random order to 60, 75 or 90 bpm for three 2-month periods and the amount of AF quantified. In addition, the exercise tolerance (ET), general well being (GWB), functional capacity (FC) and specific symptom prevalence (SSP) were assessed. The main finding of the study was that when ranked according to the amount of AF, there was no significant difference in the amount of AF according to the pacing rate. Six patients failed to tolerate pacing at 90 bpm. There were no differences in the ET, GWB, FC and SSP scores. It is concluded that those clinicians that manage patients with paroxysmal

Entities:  

Mesh:

Year:  2001        PMID: 11333047     DOI: 10.1053/eupc.2001.0160

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  3 in total

Review 1.  Pacing for atrial fibrillation.

Authors:  Chu-Pak Lau
Journal:  Heart       Date:  2003-01       Impact factor: 5.994

2.  Nonpharmacological Treatment of Atrial Fibrillation: What Is the Role of Device Therapy?

Authors:  Lucie Riedlbauchová; Václav Durdil; Jakub Honěk; Josef Veselka
Journal:  Int J Angiol       Date:  2020-04-28

3.  Effect of atrial tachyarrhythmia duration on percentage of time with atrial pacing in pacemaker patients with paroxysmal atrial fibrillation.

Authors:  Andreas Schuchert; Gaby Frost; Thomas Meinertz
Journal:  J Interv Card Electrophysiol       Date:  2004-10       Impact factor: 1.900

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.